Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer

Rhea-AI Summary

Ludwig Enterprises has filed a provisional patent for an mRNA genetic screening technique targeting breast, colon, and bladder cancers. The innovation focuses on identifying and differentiating cancers and assessing treatment effectiveness through mRNA biomarkers. These biomarkers are dynamic genetic signals that can revolutionize cancer diagnostics. The company is leveraging machine learning AI to continuously update statistical models using patient data from over 40 clinics in the U.S. CEO Marvin S. Hausman highlighted the significance of the breakthrough in tapping into the billion-dollar cancer diagnostic market. Cheek cell samples, collected noninvasively, are analyzed to detect these mRNA biomarkers.

Positive

• Ludwig Enterprises has filed a provisional patent for mRNA genetic screening in breast, colon, and bladder cancers.
• The mRNA biomarkers identified are sensitive dynamic genetic signals associated with cancer.
• The company is poised to enter the billion-dollar cancer diagnostic market.
• Utilization of machine learning AI for continuous statistical updates with patient data from over 40 clinics enhances the technology's accuracy and reliability.

Negative

• None.

SPARKS, NV / ACCESSWIRE / July 9, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce that the company has filed a provisional patent titled "mRNAs DIFFERENTIALLY EXPRESSED IN COLORECTAL CANCER, BREAST CANCER, AND BLADDER CANCER." The present invention generally relates to the use of mRNA genetic transcripts to (a) identify and differentiate between cancers, and (b) determine the effectiveness of a treatment for a cancer.The mRNA biomarkers uncovered by Ludwig are a sensitive dynamic genetic signal associated with cancer that opens the door for the company to participate in the emerging billion dollar diagnostic cancer screening market.

"Ludwig has uncovered game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman MD, CEO. "The Company continues to collect mRNA samples from over 40 multipurpose medical clinics throughout the United States. Our proprietary machine learning AI technology allows contiuous statistical updates as additional patient data is received."

Noninvasive buccal or cheek cells are easily collected using cotton tipped swabs and the cells are analyzed for levels of mRNA biomarkers, a dynamic signal associated with inflammatory diseases, such as cancer. Director of Data Sciences at Nike Inc., Dr. Kyle Ambert PhD, using machine learning artificial intelligence (AI) assisted Ludwig in the development of these dynamic sensitive signals from mRNA data contained in cheek cells. Machine learning, as used is a statistical technique for fitting models to healthcare data and to ‘continually learn and update' by training models with patient data.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor and create solutions to prevent chronic inflammation, the causative agent of illnesses, such as cancer and heart disease, which are responsible for more than 50% of deaths worldwide.

For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
marvin@ludwigent.com
www.ludwigent.com

SOURCE: Ludwig Enterprises, Inc.

View the original press release on accesswire.com

FAQ

What is Ludwig Enterprises' new patent about?

Ludwig Enterprises has filed a provisional patent for mRNA genetic screening methods for breast, colon, and bladder cancers.

How does Ludwig Enterprises' new mRNA screening technology work?

The technology identifies and differentiates cancers and assesses treatment effectiveness through dynamic mRNA biomarkers in cheek cell samples.

What is the significance of Ludwig Enterprises' new mRNA biomarkers?

The mRNA biomarkers are sensitive dynamic genetic signals that can revolutionize cancer diagnostics.

How is machine learning AI used in Ludwig Enterprises' new cancer screening technology?

Machine learning AI is used to fit models to healthcare data and continually update them as more patient data is received, enhancing accuracy and reliability.

What market is Ludwig Enterprises targeting with their new patent?

Ludwig Enterprises is targeting the billion-dollar cancer diagnostic market with their new mRNA genetic screening technology.